Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Kaposi 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Breast Neoplasms 1AIDS-related Kaposi sarcoma 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Interleukin-12 × Clear all
NCT00622401 2017-11-14

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Dana-Farber Cancer Institute

Phase 1/2 Terminated
8 enrolled 5 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡